BTTX (Better Therapeutics) EBITDA Margin %: 0.00% (As of Sep. 2023)


What is Better Therapeutics EBITDA Margin %?

Better Therapeutics BTTX EBITDA Margin % is 0.00% as of Sep. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Better Therapeutics's EBITDA for the three months ended in Sep. 2023 was $-4.50 Mil. Better Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Better Therapeutics's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

Better Therapeutics  (OTCPK:BTTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Better Therapeutics EBITDA Margin % Related Terms

Better Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Better Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Better Therapeutics EBITDA Margin % Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
-31,672.22 -75,737.50 0.00 0.00

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BTTX vs CYCN, CELZ, NRSN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Better Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's EBITDA Margin % falls into.


Better Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Better Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-35.533/0
= %

Better Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-4.5/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Better Therapeutics (BTTX) has a EBITDA Margin % of 0.00% as of Sep. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' EBITDA Margin % too high?
Better Therapeutics' current EBITDA Margin % is 0.00%.
How does Better Therapeutics' EBITDA Margin % compare to CYCN and CELZ?
Better Therapeutics' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Better Therapeutics and its competitors. Better Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current EBITDA Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Better Therapeutics Business Description

Address 548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.